Blastic transformation of BCR‐ABL1 positive chronic myeloid leukaemia through acquisition of CBFB‐MYH11 and mutant KIT

John V. Asimakopoulos Maria K. Angelopoulou Maria-Panagiota Arapaki Alexandros Kanellopoulos Maria Dimou Xanthoula Giakoumis Eliana Konstantinou Marina Belia Chrysovalantou Chatzidimitriou Sotirios Sachanas Theodoros Iliakis Marie-Christine Kyrtsonis Marina P. Siakantaris Nora-Athina Viniou Eleni Variamis Flora N. Kontopidou Gerassimos A. Pangalis Panayiotis Panayiotidis Kostas Konstantopoulos Theodoros P. Vassilakopoulos Department of Haematology and Bone Marrow Transplantation Unit, National and Kapodistrian University of Athens, School of Medicine, Laikon General Hospital, 1st Propedeutic Department of Internal Medicine, National and Kapodistrian University of Athens, School of Medicine,Laikon General Hospital, Department of Haematology, Athens Medical Center, Psychikon Branch, 1st Department of Internal Medicine, Hematology Unit, National and Kapodistrian University of Athens, School of Medicine, Laikon General Hospital and Second Department of Internal Medicine, National and Kapodistrian University of Athens,Hippokration General Hospital, Athens, Greece. E-mail: theopvass@hotmail.com

[1]  D. Scott,et al.  Validation of a simplified international prognostic score (IPS‐3) in patients with advanced‐stage classic Hodgkin lymphoma , 2019, British journal of haematology.

[2]  S. Kimura,et al.  BCR-ABL1- and CBFB-MYH11-positive chronic myeloid leukemia presenting with primary blast crisis and marrow fibrosis , 2019, Annals of Hematology.

[3]  S. Mustjoki,et al.  Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia , 2019, Leukemia.

[4]  K. Metzeler,et al.  Gene mutations and clonal architecture in myelodysplastic syndromes and changes upon progression to acute myeloid leukaemia and under treatment , 2018, British journal of haematology.

[5]  H. Kantarjian,et al.  Myeloid neoplasms with concurrent BCR‐ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm , 2017, American journal of hematology.

[6]  K. Metzeler,et al.  Molecular Genetic Characterization of Individual Cancer Cells Isolated via Single-Cell Printing , 2016, PloS one.

[7]  S. Ogawa,et al.  Single cell genotyping of exome sequencing-identified mutations to characterize the clonal composition and evolution of inv(16) AML in a CBL mutated clonal hematopoiesis. , 2016, Leukemia research.

[8]  B. Dörken,et al.  BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features , 2016, Annals of Hematology.

[9]  H. Kantarjian,et al.  Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. , 2016, Blood.

[10]  O. Abdel-Wahab,et al.  Comprehensive mutational profiling of core binding factor acute myeloid leukemia. , 2016, Blood.

[11]  F. Ravandi,et al.  t(9;22) as secondary alteration in core‐binding factor de novo acute myeloid leukemia , 2015, American journal of hematology.

[12]  M. Caligiuri,et al.  inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations. , 2013, Blood.

[13]  L. Bullinger,et al.  Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG). , 2013, Blood.

[14]  R. Gascoyne,et al.  International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Martin C. Müller,et al.  Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. , 2011, Blood.

[16]  H. Kantarjian,et al.  inv(16)(p13q22) in chronic myelogenous leukemia in blast phase: a clinicopathologic, cytogenetic, and molecular study of five cases. , 2005, American journal of clinical pathology.

[17]  W. Hiddemann,et al.  KIT exon 8 mutations associated with core-binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor. , 2005, Blood.